natgillin/translations-raw huggingface dataset:
The method according to Claim 7, wherein the compound (2) is at least one compound selected from the group consisting of a polyoxyalkylene sorbitan fatty acid ester and a polyoxyalkylene fatty acid ester. 
Postupak u skladu s patentnim zahtjevom 7, naznačen time, da je spoj (2) barem jedan spoj odabran iz skupine koju čine polioksialkilen sorbitan ester masne kiseline i ester polioksialkilen masne kiseline.
The oil-based suspension according to Claim 10, wherein the compound (2) is at least one compound selected from the group consisting of a polyoxyalkylene sorbitan fatty acid ester and a polyoxyalkylene fatty acid ester. 
Suspenzija na bazi ulja u skladu s patentnim zahtjevom 10, naznačena time, da je spoj (2) barem jedan spoj odabran iz skupine koju čine polioksialkilen sorbitan ester masne kiseline i ester polioksialkilen masne kiseline.
The oil-based suspension according to Claim 10 or 11, wherein the surfactant (3) is at least one surfactant selected from the group consisting of polyoxyethylene hydrogenated castor oil, a polyoxyethylene styryl phenyl ether, a polyoxyethylene sorbitol fatty acid ester and a sorbitan fatty acid ester. 
Suspenzija na bazi ulja u skladu s patentnim zahtjevom 10 ili 11, naznačena time, da je surfaktant (3) barem jedan surfaktant odabran iz skupine koju čine polioksietilen hidrogenirano ricinusovo ulje, polioksietilen stiril fenil eter, ester polioksietilen sorbitol masne kiseline i ester sorbitan masne kiseline.
The transgenic mouse of claim 1 or 2, wherein the mouse further comprises in its genome an endogenous k light chain immunoglobulin locus comprising a replacement of endogenous Vk and Jk gene segments with unrearranged human Vλ and Jλ gene segments, and wherein the human Vλ and Jλ gene segments are operably linked to an endogenous mouse Ck gene such that the mouse expresses an immunoglobulin light chain that comprises a human λ variable region fused with a mouse k constant region. 
Genetski modificirani miš prema zahtjevu 1, naznačen time, što miš u svom genomu dodatno sadrži endogeni lokus imunoglobulina lakog lanca k koji se sastoji od zamjene endogenih Vk i Jk genskih segmenta neraspoređenim humanim Vλ i Jλ genskim segmentima, te naznačen time, što su humani Vλ i Jλ genski segmenti operativno povezani s endogenim mišjim Ck genom tako da miš izražava imunoglobulinski laki lanac koji sadrži humanu varijabilnu regiju λ spojenu s mišjom konstantnom regijom k.
The transgenic mouse of claim 7, wherein the mouse further comprises a human Vk-Jk intergenic region sequence located between the human Vλ gene segments and the human Jλ gene segments. A mouse cell comprising in its genome an endogenous λ light chain immunoglobulin locus comprising a deletion of the endogenous mouse Vλ1-Jλ3-Cλ3-Jλ1-Cλ1 gene cluster and a deletion of a region spanning from Vλ2 to Jλ2 of the endogenous mouse Vλ2-Vλ3-Jλ2-Cλ2-Jλ4-Cλ4 gene cluster. 
Mišja stanica koja u svom genomu sadrži endogeni lokus imunoglobulina lakog lanca λ koji se sastoji od brisanja endogenog mišjeg Vλ1-Jλ3-Cλ3-Jλ1-Cλ1 klastera gena i brisanja regije koja se proteže od Vλ2 do Jλ2 endogenog mišjeg Vλ2-Vλ3-Jλ2-Cλ2-Jλ4-Cλ4 klastera gena, naznačena time, što endogeni lokus imunoglobulina lakog lanca λ zadržava endogene Cλ2, Jλ4 i Cλ4 genske segmente.
An isolated anti-Epidermal Growth Factor Receptor (EGFR) antibody for use in treating a brain-resident cancer in a mammal, wherein the brain-resident cancer is selected from the group consisting of glioblastoma, medulloblastoma, meningioma, neoplastic astrocytoma and neoplastic arteriovenous malformation, and wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 164, comprises a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 166, and is conjugated to an agent selected from the group consisting of a chemical ablation agent, toxin, immunomodulator, cytokine, cytotoxic agent, and chemotherapeutic agent or drug. 
Izolirano protutijelo anti-EGFR (Epidermal Growth Factor Receptor)-(receptor epidermalnog faktora rasta), naznačeno time, da se upotrebljava u liječenju raka koji se nalazi u mozgu kod sisavca, pri čemu se rak smješten u mozgu odabire iz skupine koju čine glioblastom, meduloblastom, meningiom, neoplastični astrocitom i neoplastična arteriovenozna malformacija, te time, da protutijelo obuhvaća varijabilno područje jakog lanca koje obuhvaća aminokiselinsku sekvencu pokazanu u SEQ ID NO:164, zatim obuhvaća varijabilno područje slabog lanca koje obuhvaća aminokiselinsku sekvencu pokazanu u SEQ ID NO:166, te time, da je konjugirano na sredstvo odabrano iz skupine koju čine kemijsko ablacijsko sredstvo, toksin, imunomodulator, citokin, citotoksično sredstvo, kemoterapeutsko sredstvo i ljekovito sredstvo.
The isolated antibody for use according to claim 5, wherein the tumor is selected from the group consisting of a head tumor, a neck tumor, a breast tumor, a lung tumor, a prostate tumor, a bladder tumor, and a glioma. 
Izolirano protutijelo za uporabu prema zahtjevu 5, naznačeno time, da je tumor odabran iz skupine koju čine tumor glave, tumor vrata, tumor dojke, tumor pluća, tumor prostate, tumor mjehura i gliom.
The isolated antibody for use according to any one of claims 1-6, wherein the heavy chain variable region is attached at its C-terminal end to an IgG isotype heavy chain. 
Izolirano protutijelo za uporabu prema bilo kojem od zahtjeva 1 do 6, naznačeno time, da je varijabilno područje jakog lanca na svojem C-završnom kraju, priključeno na jaki lanac IgG-izotipa.
The isolated antibody for use according to claim 15, wherein the second agent is selected from the group consisting of a tyrosine kinase inhibitor, doxorubicin, temozolomide, cisplatin, carboplatin, nitrosoureas, procarbazine, vincristine, hydroxyurea, 5-fluorouracil, cytosine arabinoside, cyclophosphamide, epipodophyllotoxin, carmustine, and lomustine. 
Izolirano protutijelo za uporabu prema zahtjevu 15, naznačeno time, da je drugo sredstvo odabrano iz skupine koju čine inhibitor kinaze tirozina, doksorubicin, temozolomid, cisplatin, karboplatin, nitrozourea, prokarbazin, vinkristin, hidroksiurea, 5-fluorouracil, citozin-arabinozid, ciklofosfamid, epipodofilotoksin, karmustin i lomustin.
E represents CH; 
E predstavlja CH;
Use according to Claim 1, wherein the compound of formula I is represented by the formula Ia, wherein: E represents CH; 
Uporaba prema zahtjevu 1, naznačena time da je spoj s formulom I prikazan s formulom Ia, [image] pri čemu: E predstavlja CH;
Use according to Claim 2 or Claim 3, wherein, in the compound of formula la, the structural fragment is in the S - configuration at the C-atom to which R1a is attached. 
Uporaba prema zahtjevu 2 ili zahtjevu 3, naznačena time da, u spoju s formulom 1a, strukturni fragment [image] je u S-konfiguraciji na C-atomu na koji je spojen R1a.
Use according to Claim 1 or Claim 2, wherein the compound of formula I is any compound selected from: 
Uporaba prema zahtjevu 1 ili zahtjevu 2, naznačena time da spoj s formulom I je bilo koji spoj odabran iz skupa koji čine:
Use according to Claim 5, wherein the compound of formula la is any compound selected from: 
Uporaba prema zahtjevu 5, naznačena time da spoj s formulom la je bilo koji spoj odabran iz skupa koji čine:
N-[4-((R)-3-benzylpyrrolidin-1-yl)-2-methylquinolin-6-yl]benzamide, and pharmaceutically-acceptable salts and/or solvates thereof, or according to Claim 6, wherein the compound of formula la is any compound selected from: 
N-[4-((R)-3-benzilpirolidin-1-il)-2-metilkinolin-6-il]benzamid, i njihove farmaceutski prihvatljive soli i/ili njihovi solvati, ili prema zahtjevu 6, pri čemu spoj s formulom 1a je bilo koji spoj odabran iz skupa koji čine:
Use of a compound of formula I, in a combination product comprising; 
Uporaba spoja s formulom I, u kombiniranom proizvodu koji sadrži;
for compounds of formula I in which R3 represents a -N(H)C(O)R8i substituent, coupling of a corresponding compound of formula I in which R3 represents a -NH2 substituent with a compound of formula V, R8iC(O)L2 V wherein L2 represents a leaving group and R8i is as defined in Claim 1; 
reakciju spoja s formulom IV, [image] pri čemu R2 i R3 su kako je definirano u zahtjevu 1, sa spojem s formulom III, kako je gore definirano; za spojeve s formulom I u kojoj R3 predstavlja -N(H)C(O)R8i supstituent, spajanje odgovarajućeg spoja s formulom I u kojoj R3 predstavlja -NH2 supstituent sa spojem s formulom V,
(R)-pirlindole enantiomer or a pharmaceutically acceptable salt thereof, for use according to claims 3 and 4 for potentiating the effects of the at least one additional analgesic agent in the treatment of neuropathic pain. 
(R)-pirlindol enantiomer ili njegova farmaceutski prihvatljiva sol, najmenjen upotrebi prema patentnim zahtjevima 3 i 4 za potenciranje učinaka najmanje jednog dodatnog analgetskog sredstva za liječenje neuropatske boli.
An isolated anti-Epidermal Growth Factor Receptor (EGFR) antibody for use in treating a brain-resident cancer in a mammal, wherein the brain-resident cancer is selected from the group consisting of glioblastoma, medulloblastoma, meningioma, neoplastic astrocytoma and neoplastic arteriovenous malformation, and wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 164, comprises a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 166, and is conjugated to an agent selected from the group consisting of a chemical ablation agent, toxin, immunomodulator, cytokine, cytotoxic agent, chemotherapeutic agent and drug. 
Izolirano protutijelo anti-EGFR (Epidermal Growth Factor Receptor)-(receptor epidermalnog faktora rasta), naznačeno time, da se upotrebljava u liječenju raka koji se nalazi u mozgu kod sisavca, pri čemu se rak smješten u mozgu odabire iz skupine koju čine glioblastom, meduloblastom, meningiom, neoplastični astrocitom i neoplastična arteriovenozna malformacija, te time, da protutijelo obuhvaća varijabilno područje jakog lanca koje obuhvaća aminokiselinsku sekvencu pokazanu u SEQ ID NO:164, zatim obuhvaća varijabilno područje slabog lanca koje obuhvaća aminokiselinsku sekvencu pokazanu u SEQ ID NO:166, te time, da je konjugirano na sredstvo odabrano iz skupine koju čine kemijsko ablacijsko sredstvo, toksin, imunomodulator, citokin, citotoksično sredstvo, kemoterapeutsko sredstvo i ljekovito sredstvo.
The isolated antibody for use according to claim 1, wherein the brain-resident cancer is glioblastoma. 
Izolirano protutijelo za uporabu prema zahtjevu 1, naznačeno time, da se kod raka koji je smješten u mozgu, radi o glioblastomu.
The isolated antibody for use according to claim 15, wherein the second agent is selected from the group consisting of a tyrosine kinase inhibitor, doxorubicin, temozolomide, cisplatin, carboplatin, nitrosourea, procarbazine, vincristine, hydroxyurea, 5-fluorouracil, cytosine arabinoside, cyclophosphamide, epipodophyllotoxin, carmustine, and lomustine. 
Izolirano protutijelo za uporabu prema zahtjevu 15, naznačeno time, da je drugo sredstvo odabrano iz skupine koju čine inhibitor kinaze tirozina, doksorubicin, temozolomid, cisplatin, karboplatin, nitrozourea, prokarbazin, vinkristin, hidroksiurea, 5-fluorouracil, citozin-arabinozid, ciklofosfamid, epipodofilotoksin, karmustin i lomustin.
A pharmaceutical composition comprising the isolated antibody of claim 1, for use in treating a brain-resident cancer in a mammal, wherein the brain-resident cancer is selected from the group consisting of glioblastoma, medulloblastoma, meningioma, neoplastic astrocytoma and neoplastic arteriovenous malformation. 
Farmaceutski sastav, naznačen time, da obuhvaća izolirano protutijelo u skladu sa zahtjevom 1, te time, da se upotrebljava u liječenju raka koji se nalazi u mozgu kod sisavca, dok se rak smješten u mozgu odabire iz skupine koju čine glioblastom, meduloblastom, meningioma, neoplastični astrocitom i neoplastična arteriovenozna malformacija.
The pharmaceutical composition for use according to claim 17, wherein the brain-resident cancer is glioblastoma. 
Farmaceutski sastav za uporabu prema zahtjevu 17, naznačen time, da se kod raka koji je smješten u mozgu, radi o glioblastomu.
The pharmaceutical composition for use according to claim 17 or 18, wherein the agent is a cytotoxic agent. 
Farmaceutski sastav za uporabu prema zahtjevu 17 ili 18, naznačen time, da sredstvo je citotoksično sredstvo.
E is an unbranched or branched alkyl linker having 1, 2, 3, 4, 5, 6 or 7 C atoms, which may be unsubstituted or mono- or disubstituted with Hal, OH, CN or NH2, in which one CH3 group may be replaced by Cyc1, Cyc2, CONH2, CF3, and in which one, two or three CH2 groups may be replaced by -O- or -NH-, and in which one CH group may be replaced by -N-; 
E je nerazgranata ili razgranata alkilna poveznica koja ima 1, 2, 3, 4, 5, 6 ili 7 C atoma, koji mogu biti nesupstituirani ili mono- ili disupstituirani s Hal, OH, CN ili NH2, u kojoj jedna CH3 skupina može biti zamijenjena s Cyc1, Cyc2, CONH2, CF3, i u kojoj jedna, dvije ili tri CH2 skupine mogu biti zamijenjene s -O- ili -NH-, te u kojoj jedna CH skupina može biti zamijenjena s -N-;
LA is an unbranched or branched, linear saturated or partially unsaturated hydrocarbon chain having 1, 2, 3 4, 5 or 6 C atoms, wherein 1, 2 or 3 H atoms may be replaced by Hal or OH; 
LA je nerazgranati ili razgranati, ravni zasićeni ili djelomično nezasićeni lanac ugljikovodika koji ima 1, 2, 3 4, 5 ili 6 C atoma, pri čemu 1, 2 ili 3 H atoma mogu biti zamijenjeni s Hal ili OH;
Compound according to claim 1, selected from the group consisting of: 
Spoj prema zahtjevu 1, naznačen time da se bira iz skupine koja sadrži:
The compound, or pharmaceutically acceptable salt or solvate thereof, for use in the treatment of cancer according to claim 6, wherein said cancer is selected from the group consisting of brain, lung, colon, epidermoid, squamous cell, bladder, gastric, pancreatic, breast, head, neck, renal, kidney, liver, ovarian, prostate, colorectal, uterine, rectal, oesophageal, testicular, gynecological, thyroid cancer, melanoma, hematologic malignancies such as acute myelogenous leukemia, multiple myeloma, chronic myelogneous leukemia, myeloid cell leukemia, glioma and Kaposi's sarcoma. 
Spoj, ili njegova farmaceutski prihvatljiva sol ili solvat, koji je za upotrebu za liječenje raka prema zahtjevu 6, naznačen time da je navedeni rak odabran iz skupine koja sadrži rak mozga, pluća, debelog crijeva, epidermoida, rak skvamoznih stanica, rak mokraćnog mjehura, rak želuca, rak gušterače, rak dojke, rak glave, rak vrata, renalni karcinom, rak bubrega, rak jetre, rak jajnika, rak prostate, kolorektalni karcinom, rak maternice, rektuma, rak jednjaka, rak testisa, ginekološki karcinom, rak štitnjače, melanom, hematološke maligne tvorbe kao što je akutna mijelogena leukemija, multipli mijelom, kronična mijelogena leukemija, leukemija mijeloidnih stanica, gliom i Kapozijev sarkom.
Tasimelteon for use in a method of treating a patient suffering from Non 24 by entraining the patient to a 24 hour sleep-wake cycle in which the patient awakens at or near a target wake time following a daily sleep period of approximately 7 to 9 hours, wherein said method comprises internally administering to the patient 20 to 50 mg of tasimelteon, the tasimelteon is administered orally once daily 0.5 to 1.5 hours before a target sleep time and the patient is light perception impaired. 
Tasimelteon za upotrebu u postupku liječenja pacijenta koji pati od Non-24 (24-satnog poremećaja spavanja) ubacivanjem pacijenta u 24-satni ciklus san-budnost, u kojem je pacijent budan ili je blizu ciljanog vremena budnosti poslije dnevnog perioda spavanja od približno 7 do 9 sati, naznačen time da navedeni postupak sadrži interno davanje pacijentu 20 do 50 mg tasimelteona, tasimelteon se daje oralno jednom dnevno 0,5 do 1,5 h prije ciljanog vremena spavanja i pacijent je ima slabu percepciju svijetla.
The method of claim 1 or 2, further comprising the step of (c) removing said second protecting group from said 5'-hydroxyl group, under conditions which do not deprotect said nucleoside base or said 3'-amino group. 
Postupak prema zahtjevu 1 ili 2, naznačen time, da nadalje obuhvaća korak (c) odstranjivanje spomenute druge zaštitne skupine iz spomenute 5’-hidroksil-skupine, pod takvim uvjetima u kojima se neće poništiti zaštita spomenute nukleozidne baze ili spomenute 3’-amino-skupine.
The method of claim 1 or 2, wherein said first protecting group is an acid labile group. 
Postupak prema zahtjevu 1 ili 2, naznačen time, da je prva zaštitna skupina jedna kiselinski labilna skupina.
The method of claim 12, wherein said monomer is a 2',3'-dideoxy monomer, such that said 2' group is hydrogen. 
Postupak prema zahtjevu 12, naznačen time, da spomenuti monomer je 2’,3’-dideoksi-monomer, takav da se kod navedene 2’-skupine radi o vodiku.
A method of preparing an adenosine, guanosine or cytidine monomer having a free 5'-hydroxyl group, a protected nucleoside base, and a protected 3'-amino group, wherein said base and said 3'-amino group are orthogonally protected, the method comprising: 
Postupak priprave monomera adenozina, guanozina ili citidina, koji ima jednu slobodnu 5’-hidroksil-skupinu, jednu zaštićenu nukleozidnu bazu i jednu zaštićenu 3’-amino-skupinu, pri čemu su navedena nukleozidna baza i navedena 3’-amino-skupina ortogonalno zaštićene, naznačen time, da taj postupak obuhvaća sljedeće korake:
The method of claim 24, wherein said first protecting group is a fluorenylmethoxycarbonyl group or a derivative of a fluorenylmethoxycarbonyl group. 
Postupak prema zahtjevu 24, naznačen time, da se kod navedene prve zaštitne skupine radi o fluorenilmetoksikarbonil-skupini ili derivatu fluorenilmetoksikarbonil-skupine.
An adenosine, guanosine or cytidine monomer having a protected 3'-amino group which is protected with an acid-labile group or a fluorenylmethoxycarbonyl group or a derivative of a fluorenylmethoxycarbonyl group and a nucleoside base which is protected with a dialkyl-, di(cycloalkyl)-, or di(aralkyl)-formamidinyl group, wherein the 5'-hydroxyl group is unprotected, or is protected such that it can be deprotected under conditions which do not deprotect said nucleoside base or said 3'-amino group. 
Monomer koji je adenozin-, guanozin- ili citidin-monomer, naznačen time, da ima zaštićenu 3’-amino-skupinu koja je zaštićena s kiselinski labilnom skupinom ili fluorenilmetoksikarbonil-skupinom ili derivatom fluorenilmetoksikarbonil-skupine, i nukleozidnu bazu koja je zaštićena s dialkil-, di(cikloialkil)- ili di(aralkil)-formamidinil-skupinom, pri čemu je 5’-hidroksil-skupina nezaštićena, ili je zaštićena tako da joj se može odstraniti zaštita, pod uvjetima u kojima se neće poništiti zaštita navedene mukleozidne baze ili navedene 3’-amino-skupine.
The monomer of claim 31, wherein the dialkyl or dicycloalkyl formamidinyl group is such that the alkyl is C1-C4 alkyl and the cycloalkyl is C5-C6 cycloalkyl. 
Monomer prema zahtjevu 31, naznačen time, da se kod dialkil-, ili dicikloalkil-formamidinil-skupine radi o takvoj skupini, gdje alkil je C1-C4-alkil, a cikloalkil je C5-C6-cikloalkil.
The monomer of claim 31, wherein said acid labile protecting group is a triarylmethyl group. 
Monomer prema zahtjevu 31, naznačen time, da navedena kiselinski labilna zaštitna skupina je triarilmetil-skupina.
The monomer of claim 31, wherein said nucleoside base is protected with a dimethylformamidinyl group or a dibenzylformamidinyl group. 
Monomer prema zahtjevu 31, naznačen time, da je navedena nukleozidna baza zaštićena s jednom dimetil-formamidinil-skupinom ili jednom dibenzil-formamidinil-skupinom.
wherein the osmolarity of said first solution is higher than the osmolarity of said second solution; 
pri čemu je osmolarnost od navedene prve otopine, veća nego osmolarnost od navedene druge otopine;
generating a first fluid stream comprising said first solution; 
generiranje prvog fluidnog toka koji obuhvaća navedenu prvu otopinu;
continuously combining said first and second fluid streams into a third fluid stream through the use of a T-joint connected to a static mixer; and separating the cells from the third fluid stream which comprises the released periplasmic protein, wherein separation uses a device for the separation of contents of a fluid based upon size or density. 
neprekidno sastavljanje navedenog prvog i navedenog drugog fluidnog toka u treći fluidni tok, kroz uporabu spojnog T-komada spojenog na statički mikser; i odvajanje stanica iz trećeg fluidnog toka, koje obuhvaćaju oslobođeni periplazmatski protein, pri čemu se za odvajanje upotrebljava uređaj za odvajanje sadržaja iz fluida na osnovi veličine ili gustoće.
The method according to any one of claims 1 to 3 wherein the second solution is a high molarity slurry selected from the group consisting of a high sugar or salt concentration. 
Postupak prema bilo kojem od zahtjeva 1 do 3, naznačen time, da navedena druga otopina je emulzija visoke molarnosti, koja je odabrana iz skupine koja se sastoji od visoke koncentracije šećera ili soli.
continuously combining the first and second fluid streams into a third fluid stream through the use of a T-joint connected to a static mixer; and separating the cells from the third fluid stream which comprises the released periplasmic protein, wherein separation uses a device for the separation of contents of a fluid based upon size or density; 
neprekidno sastavljanje prvog i drugog fluidnog toka u treći fluidni tok, putem uporabe spojnog T-komada spojenog na statički mikser; i odvajanje stanica iz trećeg fluidnog toka, koje obuhvaćaju oslobođeni periplazmatski protein, pri čemu se odvajanje vrši uporabom uređaja za odvajanje sadržaja iz fluida na osnovi veličine ili gustoće;
The method according to claim 6, wherein the high molarity slurry is selected from the group consisting of a high sugar or salt concentration and/or the low molarity shock buffer has a pH of from about 5 to about 9. 
Postupak prema zahtjevu 6, naznačen time, da je emulzija visoke molarnosti odabrana iz skupine koja se sastoji od visoke koncentracije šećera ili soli i/ili time, da šok-pufer niske molarnosti ima pH-vrijednost od oko 5 do oko 9.
The method according to claim 6 or 7, further comprising: administering a heat exchanger; a solvent; or a chemical treatment, before or after osmotic pressure is released from the cells. 
Postupak prema zahtjevu 6 ili 7, naznačen time, da on dodatno obuhvaća sljedeće: primjenu izmjenjivača topline; otapalo; ili kemijsku obradu, prije ili nakon što se osmotski tlak otpusti iz stanica.
A polypeptide for use according to claim 1, which comprises a variant of an Rv1753c protein sequence having at least 90% identity to SEQ ID No: 1 or 3-7. 
Polipeptid namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što sadrži varijantu slijeda proteina Rv1753c koji je najmanje 90% istovjetan SEQ ID No: 1 ili 3-7.
An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide which comprises: an Rv1753c protein sequence of SEQ ID No: 1 or 3-7; a variant of an Rv1753c protein sequence having at least 90% identity to SEQ ID No: 1 or 3-7; or 
Izolirani polinukleotid, naznačen time što sadrži nukleinskokiselinski slijed koji kodira polipeptid koji sadrži: slijed proteina Rv1753c sa SEQ ID No: 1 ili 3-7; varijantu slijeda proteina Rv1753c koji je najmanje 90% istovjetan SEQ ID No: 1 ili 3-7; ili
A polynucleotide for use according to claim 12, comprising a nucleic acid sequence encoding a polypeptide which comprises an Rv1753c protein sequence of SEQ ID No: 1 or 3-7. 
Polinukleotid namijenjen upotrebi u skladu s patentnim zahtjevom 12, naznačen time što sadrži nukleinskokiselinski slijed koji kodira polipeptid koji sadrži slijed proteina Rv1753c sa SEQ ID No: 1 ili 3-7.